Pancreatic cancer biomarkers and uses thereof
The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer generally and pancreatic cancer specifically. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer generally or pancreatic cancer specifically. In another aspect, methods are provided for diagnosing pancreatic cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having pancreatic cancer, or the likelihood of the individual having pancreatic cancer is determined, based on the at least one biomarker value. In a further aspect, methods are provided for diagnosing cancer generally in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 19, wherein the individual is classified as having cancer generally, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.
1. A method for detecting protein levels of a set of proteins in a human, the method comprising:
contacting a biological sample from the human with a set of N capture reagents,
wherein each capture reagent specifically binds to a different protein of a set of N proteins, wherein N=4 to 65, and wherein the set of proteins comprises at least HAMP, CTSB, THBS4, CCL23, and measuring the level of each protein of the set of proteins based on measurement of the capture reagents;
wherein, the biological sample is selected from the group consisting of whole blood, plasma, and serum, and wherein the measuring of the capture reagents is performed with a capture reagent-based assay; and
analyzing the level of each protein measured with an algorithm to determine risk of pancreatic cancer in the human.
2. The method of claim 1 , wherein the set of proteins, in addition to HAMP, CTSB, THBS4 and CCL23, comprises one or more proteins selected from the group consisting of C5, MMP-7, C2, CRP, PSA-ACT and GDF-11.
3. The method of claim 1 , wherein the human is high risk for pancreatic cancer due to smoking, alcohol consumption or family history of pancreatic cancer.
4. The method of claim 1 , wherein the capture reagent is selected from the group consisting of an aptamer and an antibody.
5. The method of claim 1 , wherein the capture reagent is an aptamer.
6. The method of claim 1 , wherein the capture reagent-based assay is an aptamer-based assay.
7. The method of claim 1 , wherein said analyzing the level of each protein measured with an algorithm comprises application of a classification algorithm.
8. The method of claim 1 , wherein said analyzing the level of each protein measured with an algorithm comprises application of a naïve Bayes classification.